ziprasidone has been researched along with citalopram in 19 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (42.11) | 29.6817 |
2010's | 11 (57.89) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Jia, L; Sun, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Sen, S; Sinha, N | 1 |
Andreasson, T; Mattsson, C; Sonesson, C; Waters, N | 1 |
Peters, JU | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Andersen, MP; Hogg, S; Pouzet, B | 1 |
Varma, A; Wickham, R | 1 |
Werremeyer, A | 1 |
Baer, L; Bobo, WV; Fava, M; Jaeger, A; Papakostas, GI; Shelton, RC; Swee, MB | 1 |
Nelson, JC | 1 |
Baer, L; Fava, M; Ionescu, DF; Meade, KH; Papakostas, GI; Shelton, RC; Swee, MB | 1 |
Baer, L; Bobo, WV; Curren, L; Fava, M; Mischoulon, D; Papakostas, GI; Shelton, RC | 1 |
2 review(s) available for ziprasidone and citalopram
Article | Year |
---|---|
Polypharmacology - foe or friend?
Topics: Animals; Communicable Diseases; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Polypharmacology; Safety | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for ziprasidone and citalopram
Article | Year |
---|---|
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Thiazoles; Treatment Outcome | 2015 |
Ziprasidone augmentation for anxious depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Thiazoles; Young Adult | 2016 |
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Electrocardiography; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Selective Serotonin Reuptake Inhibitors; Thiazoles; Weight Gain; Young Adult | 2017 |
14 other study(ies) available for ziprasidone and citalopram
Article | Year |
---|---|
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
Topics: Animals; Behavior, Animal; Brain; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Locomotion; Molecular Structure; Psychotic Disorders; Rats; Serotonin; Serotonin Receptor Agonists; Structure-Activity Relationship | 2012 |
Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antipsychotic Agents; Bupropion; Citalopram; Desipramine; Dextroamphetamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Male; Norepinephrine; Piperazines; Rats; Rats, Wistar; Reflex, Startle; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2005 |
Ziprasidone-associated mania in a case of obssessive-compulsive disorder.
Topics: Anticonvulsants; Bipolar Disorder; Citalopram; Clonazepam; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Thiazoles | 2007 |
Ziprasidone and citalopram use in pregnancy and lactation in a woman with psychotic depression.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Citalopram; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Lactation; Male; Milk, Human; Piperazines; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2009 |
Adjunctive Ziprasidone in Major Depression and the Current Status of Adjunctive Atypical Antipsychotics.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Piperazines; Thiazoles | 2015 |
ADDENDUM.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Piperazines; Thiazoles | 2015 |